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ABSTRACT
Objective: The goal of this analysis was to evaluate the
impact of gout, a painful inﬂammatory arthritis condition, on
an employed population’s health-related work absence and
objectively measured productivity output.
Methods: Payroll, demographic, medical, pharmaceutical,
sick leave, short- and long-term disability, and workers’ com-
pensation data were collected from multiple large employers
with employees widely dispersed across the United States.
Data were collected during the time period of 2001 to 2004
from approximately 300,000 employees. Objective produc-
tivity output data were also available for a subset of employ-
ees (captured electronically in the form of units of work
processed per person). T-tests and chi-square tests were
used to compare demographic data. Two-stage multivariate
regression models were used to compare annual work
absence and at-work productivity between employees with
and without gout, while controlling for group differences in
demographics, salary, other work-related variables, and
comorbidities (using the Charlson Comorbidity Index).
Results: The annual prevalence of gout was 4.7 per 1000
employees from 2001 to 2004. Employees with gout had
4.56 more annual absence days for all categories of health-
related work absence than those without gout. Objective
productivity (units of work processed) results were only
available for a small subsample of employees (86 with gout
and 27,472 without gout). Employees with gout processed
3.51% fewer units per hour worked and 2.38% fewer units
per year than employees without gout (nonsigniﬁcant at
P = 0.49 and P = 0.78, respectively).
Conclusion: This study suggests that gout has a substantial
impact on work absence and may also negatively impact
productivity.
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Introduction
Gout is now the most common form of inﬂammatory
joint disease in men aged 40 years and older [1], and is
thought to affect approximately 5.1 million US adults
[2]. Prevalence of gout is thought to be increasing
[3–8], in part, because of an increase in overall longev-
ity, as well as an increase in multiple contributory risk
factors, including obesity, alcohol consumption, high
purine intake, hypertension, increased prevalence of
end-stage renal failure, and use of certain predisposing
medications such as aspirin and thiazide diuretics [9].
Patients with gout present, particularly in the acute
and recurrent phases, with rapid onset of severe pain,
accompanied by swelling and erythema in the affected
joint. The involved joint is usually monoarticular
(90%) and found in the lower extremity [10,11]. Pain
is considered the primary symptom, but treatment of
the condition is aimed at treating both pain and
inﬂammation [12]. Even with treatment, it usually
takes 5 to 7 days for symptoms to resolve [11,12].
Patients generally enter an asymptomatic phase
between episodes, and with time if left untreated,
attacks are more likely to become polyarticular, more
frequent, and of longer duration [10]. Ultimately, and
particularly when hyperuricemia is poorly controlled,
a patient may develop an advanced, chronic picture,
with continuous pain and symptoms from chronic
arthropathy [13]. This advanced picture may also
include the comorbid conditions of urolithiasis, urate
nephropathy, and/or tophi [14].
As the incidence and prevalence of gout appear to
be increasing, the effect of this disease on employers in
terms of health-related work absence and producti-
vity requires evaluation. Studies have conﬁrmed that
patients with musculoskeletal disease reduce work
hours, take breaks, or may even be forced to change
jobs, in efforts referred to as “self-management” or
“behavioral coping” to deal with pain and disability
[15–17]. Stewart et al. have evaluated the effect of pain
from arthritis on work absence and reduced perfor-
mance using data collected between 2001 and 2002
using the American Productivity Audit, a national
survey of the US workforce [18]. They found that
approximately 2% of subjects suffered a loss in pro-
ductivity due to pain from arthritis, with a mean loss in
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productive time (either from actual absence or pres-
ence at work with a reduction in performance) of
5.2 hours per week. Unfortunately, this study does
not differentiate these results for inﬂammatory versus
noninﬂammatory arthritis, conditions that have very
different clinical presentations and long-term conse-
quences [19]. In addition, the analysis only examined
the effect of pain on these variables, and not the effect
of the overall condition. Furthermore, it does not
examine objective work output data when estimating
productivity loss. An additional study on arthritis and
associated joint disorders (AJD) in an employed popu-
lation found employees with AJD produced 4% fewer
annual work units (P < 0.05), had higher annual
absence costs ($84), and more short- and long-term
disability than employees without AJD [20].
The goal of this analysis was to evaluate the impact
of gout, an inﬂammatory arthritis condition, on an
employed population’s health-related work absence
and productivity output.
Materials and Methods
Data Source
A retrospective study was utilized using two compari-
son cohorts selected from the Human Capital Manage-
ment Services Research Reference Database (HCMS
RRDb): a cohort of employees with gout, and a cohort
of employees without gout. This database of approxi-
mately 300,000 employees is compiled from several
large national US employers, and represents retail,
service, manufacturing, and ﬁnancial industries. The
HCMS RRDb includes demographic and claims data
from 2001 to 2004 for direct medical care, prescrip-
tion drugs, absence, disability, and workers’ compen-
sation. There are also data on employee-speciﬁc
at-work productivity for a subset of the overall popu-
lation. This subset of employees performs work that
can be measured in units of work processed per hour.
The demographic data include age, tenure (years with
current employer), sex, exempt status (indicating a
salaried versus hourly pay schedule), marital status,
annual salary, full- or part-time status, and geographic
region (deﬁned by the ﬁrst digit of the employee’s ZIP
code). The HCMS RRDb contains all medical claims
for subjects allowing an analysis of comorbid
conditions using Agency for Healthcare and Research
Quality’s 17 major diagnostic categories and 261
speciﬁc categories [21]. This database has been used
previously for this type of research [22].
The cohort of employees with gout was selected
from the HCMS RRDb if they had an International
Classiﬁcation of Diseases-9 (ICD-9) code 274.xx for
the diagnosis (primary, secondary, or tertiary) during
the calendar years of 2001 to 2003. The subject’s
index date was deﬁned as the date the employee was
ﬁrst associated with the gout ICD-9 diagnosis.
Employees without gout, the control cohort, were
selected from the subjects that did not have a primary,
secondary, or a tertiary ICD-9 code for gout (274.xx).
The index date for this cohort was assigned based on
the average index date of the employees with gout.
Employees from both cohorts were required to have
continuous eligibility for medical and prescription ben-
eﬁts for at least 1 year after the index date. Annual
outcomes data for each analysis were measured for the
year immediately after the index date for both cohorts.
Statistical Analysis
The mean values for the demographic data of the two
cohorts were calculated and compared using t-tests or
chi-square tests. These data included age (at index
date), sex, annual salary, tenure (years with current
employer as of the index date), exempt status, full- or
part-time status, and marital status. Demographic data
on race were not available for all records, and were
only used to help control for possible confounding
factors in regression modeling. Demographic data
were also available and compared for region, as
deﬁned by the ﬁrst number of the subject’s ZIP code.
All t-test comparisons were considered statistically sig-
niﬁcant when P  0.05.
Regression models were used to compare health-
related work absence and lost at-work productivity
between the two cohorts. The regression models con-
trolled for the confounding factors of age, sex, tenure,
marital status, race, exempt status, full- or part-time
status, salary, and region. In addition, the models were
controlled for comorbidities using a Charlson Comor-
bidity Index score [23].
Variables modeled in the work absence analyses
included lost days from work due to sick leave (SL),
short-term disability (STD), long-term disability
(LTD), and workers’ compensation indemnity (WC). A
two-stage regression methodology was utilized for
each of these dependent variables as these data were
highly skewed, had nonconstant variance, and had
many observations in which values were zero [24,25].
Logistic regression was used in the ﬁrst stage model to
predict the likelihood of absence during the year after
the index date (dependent variable was 1 if the
employee had more than 0 absence days and was 0
otherwise). In the second stage, a generalized linear
model (with a gamma distribution and log link) was
used to estimate average annual lost days for those
employees with work absences. The results were then
combined to yield estimates of annual lost days for all
employees in the cohort. Only employees eligible for a
speciﬁc work absence beneﬁt were included in regres-
sion models for that beneﬁt.
Productivity data for subjects used in this analysis
were only available for a subset of the HCMS RRDb
(those with values provided for number of units pro-
cessed per hour). These included 86 employees with
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gout and 27,632 employees without gout. The analysis
allowed for examination of productivity while at work
(hourly productivity) and for a 12-month period (total
annual productivity). The at-work productivity analy-
ses were performed using only the second-stage regres-
sion modeling described above. Subjects with hourly
or annual productivity values greater than 4 standard
deviations from the mean were removed (0 employees
with gout and 160 employees without gout were
removed from the hourly analysis, and 0 employees
with gout and 117 employees without gout were
removed from the annual analysis) [22].
SAS System for Windows version 9.1 (SAS Institute,
Inc., Cary, NC, USA) was used to generate all statisti-
cal analysis.
Results
The analysis identiﬁed 1171 employees with gout and
247,867 employees without gout yielding a prevalence
of approximately 4.7 per 1000 employees. The means
and conﬁdence intervals for demographic data for
both cohorts are given in Table 1. All t-test and chi-
square test comparison results between both cohorts
were found to be signiﬁcant at P  0.05 level. Employ-
ees with gout were older than those without gout
(5.5 years) and 56.5% more likely to be male. They
were more likely to be Caucasian, and to be married.
Employees with gout had higher salaries and longer
tenure, were more likely to have exempt status, and
were more likely to be employed full time. It was also
found that employees with gout were more likely
to live in the Northeast region of the United States
(ZIP codes starting with 0 or 1). They were
less likely to live in ZIP code regions starting with
3 (Florida, Alabama, Mississippi, Tennessee, and
Georgia), ZIP code regions starting with 4 (Kentucky,
Indiana, Ohio, and Michigan), and ZIP code regions
starting with 9 (Alaska, Hawaii, Washington, Oregon,
and California) (P  0.05).
Figure 1 displays the annual lost days per employee
with gout versus the employee without gout. Employ-
ees with gout had 2.78 more days of SL than employ-
ees without gout (P < 0.0001). They had 3.03 more
days of STD absence (P = 0.0003). Employees without
gout had 1.45 more days of absence associated with
LTD than did employees with gout (P < 0.0001). Dif-
ferences in lost days associated with WC were not
statistically signiﬁcant. WC days were nonsigniﬁcantly
greater for employees with gout (0.2 more days). The
total number of absence days for all categories of
disability for employees with gout was 14.39 days
versus 9.83 days for employees without gout, or a
4.56-day difference.
Table 2 displays the objectively measured produc-
tivity comparison of units processed per hour worked
and units processed per year adjusted for age, tenure,
sex, marital status, race, exempt status, full- or part-
time status, salary, region, and Charlson Comorbidity
Index. Employees with gout averaged 3.51% fewer
Table 1 Demographic statistics for employees with and without gout (during the year after the subject’s index date*)
Variable
Employees with gout Employees without gout
n Mean Lower 95% CI Upper 95% CI n Mean Lower 95% CI Upper 95% CI
Age (at index date)†,‡ 1,171 45.91 45.40 46.43 247,849 40.41 40.37 40.45
Male sex (%)† 1,171 85.0 82.9 87.0 247,867 54.3 54.1 54.5
Annual salary ($)† 1,145 61,361 57,622 65,100 244,397 50,314 49,942 50,686
Tenure (at index date)†,‡ 1,171 12.79 12.23 13.36 247,867 9.73 9.70 9.76
Exempt (%)†,§ 1,171 36.0 33.2 38.7 247,859 29.5 29.3 29.7
Full-time (%)† 1,171 94.4 93.0 95.7 247,867 86.6 86.5 86.8
Race 736 170,951
White (%)† 71.7 68.5 75.0 65.4 65.1 65.6
Black (%)† 15.5 12.9 18.1 19.6 19.4 19.8
Hispanic (%)† 5.8 4.1 7.5 9.7 9.5 9.8
Married (%)† 1,087 66.1 63.2 68.9 225,037 56.6 56.4 56.8
ZIP code ﬁrst digit = 1,171 247,867
0† (%) 17.9 15.7 20.1 12.2 12.1 12.3
1† (%) 17.0 14.8 19.1 14.5 14.4 14.7
2 (%) 13.3 11.4 15.3 13.6 13.5 13.7
3† (%) 17.1 14.9 19.2 21.5 21.3 21.6
4† (%) 3.8 2.7 4.8 5.1 5.0 5.2
5 (%) 0.4 0.1 0.8 0.7 0.7 0.7
6 (%) 2.8 1.9 3.8 3.1 3.0 3.2
7 (%) 13.1 11.1 15.0 12.9 12.7 13.0
8 (%) 5.0 3.8 6.3 4.5 4.5 4.6
9† (%) 9.6 7.9 11.3 11.8 11.7 12.0
*For employees with gout, the index date is the date of the ﬁrst gout diagnosis (ICD-9 274.xx) in the study period. For employees without gout, the index date is the average
index date from the group of employees with gout.
†Differences evaluated using t-tests or chi-square tests and found to be signiﬁcant (P 0.05).
‡Values given in years.
§Exempt status (indicating a salaried vs. hourly pay schedule).
CI, conﬁdence interval; n, sample size.
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units processed per hour worked than those without
gout, but this difference was found to be nonsigniﬁcant
(P = 0.4939). The difference in units processed per
year (2.38% fewer units for employees with gout) was
also nonsigniﬁcant (P = 0.7758).
Discussion
This analysis, using a comprehensive source of claims
data including metrics for health-related work absence
and at-work productivity, adds to the limited literature
of the impact of gout on employers in the United
States. The results found that the overall prevalence of
gout in this employed population was 4.7 per 1000
employees. This is consistent with other physician-
derived prevalence rates that have been reported in the
literature [4,7,26,27]. Physician-reported cases of gout
are lower than self-reported cases, with current self-
reported prevalence in the United States documented
at 22.4 per 1000 adults aged 45 to 64 years [4]. The
lower rate of cases reported by physicians may lead
to an underestimation of the work absence and
productivity-loss in this study, as employees with gout
who self-treat and are subsequently not reported in
this database may not only have frequent absences
from work, but also be less productive because of the
condition.
The results of this analysis also revealed that in this
population of employed workers, employees with gout
were older and more likely to be male, results that are
consistent with current literature [1,28]. More impor-
tantly, from the perspective of the employer, employees
with gout in this population had higher salaries, longer
tenure, and were more likely to have exempt status and
full-time status. These ﬁgures are important for several
reasons. As suggested above, the data may suggest that
there is an element of self-management that is occur-
ring in the gout cohort, as has been previously docu-
mented in patients with arthritis [29]. Employees with
gout may be unable to maintain positions that require
strenuous activity, positions that are often paid on an
hourly basis or are more likely to include overtime
status. They are therefore less likely to choose posi-
tions that include manual labor, managing their disease
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Figure 1 Comparison of annual lost days per employee. Lost days were calculated for employees eligible for each speciﬁc beneﬁt for each regression
model for that beneﬁt, and were adjusted controlling for age, tenure, sex, marital status, race, exempt status, full- or part-time status, region, and Charlson
Comorbidity Index. For employees with gout, the index date is the date of the ﬁrst gout diagnosis (ICD-9 274.xx) in the study period. For employees
without gout, the index date is the average index date based on the cohort of employees with gout. Sample sizes of eligible employees with gout and
without gout were: 600 and 123,461 employees for sick leave; 484 and 102,234 for short-term disability; 822 and 177,477 for long-term disability; and 1085
and 224,723 for workers’ compensation, respectively.
Table 2 Objective productivity comparison of units of work processed per hour and per year*,†
Adjusted
units
processed
Employees with gout Employees without gout
D in means P-value‡Mean Lower 95% CI Upper 95% CI Mean Lower 95% CI Upper 95% CI
Per hour n = 86 n = 27,472
17.85 16.03 19.67 18.50 18.39 18.60 0.65 0.4939
Per year n = 86 n = 27,515
27,382 23,635 31,329 28,049 27,829 28,268 566.4 0.7758
*For employees with gout, the index date is the date of the ﬁrst gout diagnosis (ICD-9 274.xx) in the study period. For employees without gout, the index date is the average
index date from the cohort of employees with gout.
†The subsets were analyzed (restricted to those employees with productivity data) using regression models adjusted for age, tenure, sex, marital status, race, exempt status, full-
or part-time status, salary, region, and Charlson Comorbidity Index. Outliers (>4 standard deviations) were removed.
‡Signiﬁcant at P 0.05.
CI, conﬁdence interval.
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by the amount of activity they perform. This is also
suggested by the small sample size of subjects that are
included in the subset of employees with gout that are
employed in positions that allow for measurement of
productivity in units per hour, positions that often
include manual labor. Of equal interest to the
employer are the data which show that gout employees
have higher salaries than those without gout. Recent
studies designed to capture variations in ranges of
salary indicate that with increasing salary (especially at
levels $50,000), lost productivity, as measured in
percentage of lost productive time in hours, may
poorly reﬂect true lost productive time cost in dollars
[18]. Additionally, differences in gout prevalence were
found for different regions in the United States. Gout
prevalence was relatively higher in the Northeast and
relatively lower in the Southeast, Midwest, and West
Coast regions. These differences may be due to lifestyle
and factors as such as alcohol intake that varies
throughout the country [30–32].
Not surprisingly, SL and STD absences are signiﬁ-
cantly greater for employees with gout. Absence due to
workers’ compensation was statistically even between
the two cohorts, indicating that gout may not increase
an employee’s likelihood of being injured on the job.
LTD absences, however, were higher for employees
without gout than for employees with gout. One
explanation may be that LTD claims are rare, yet result
in a large number of lost days from work. The results
of the analysis revealed that over all health-related
work absence beneﬁts, the cohort of employees with
gout lost almost 5 more days of work on average
annually than did employees without gout. Using this
incremental value and the study’s prevalence rate of
4.7 per 1000 employees, an annual total of additional
lost days in persons with gout can be conservatively
projected across the US civilian labor force (a total of
144.9 million persons in 2002) [33] at approximately
3.105 million additional lost days. Another way to
undertake this analysis is to calculate the days lost by
using values for the population insured by an employer
in the United States [34,35]. In 2002, approximately
64% of adults aged 18 to 64 years, or an estimated
114.9 million population, fell into this insured cat-
egory. Using this population number, the overall incre-
mental lost days in persons with gout is estimated at
2.463 million days.
The productivity comparison per hour and per year
between employees with gout and without gout, over a
small subset of the database that included these data,
did not reveal signiﬁcant differences between the two
groups. As noted above, this is a group of employees
who are employed in positions that generally require
more strenuous activity, and the small sample size may
reﬂect self-selection of employees with severe gout
away from such positions. Only 7.3% of employees
with gout fell into this subset of employees with pro-
ductivity data (86 persons out of a total of 1171)
versus 11.1% of employees without gout (27,515
persons out of a total of 247,849). Upon examination
of these results, it may be hypothesized that the popu-
lation that is still capable of this type of more strenu-
ously physical employment is in an earlier stage of the
disease, and suffers less from pain and has less work
impairment.
Limitations of this analysis include the fact that
the study was not designed to evaluate some unit of
measure of productivity for “white collar” workers
with gout. With increasing pain and severity of gout,
disability increases. While the study was able to
capture health-related work absence for most employ-
ees, it was only able to capture objectively measured
work output data for a subset of “blue collar”
workers. Additional research is needed to better
measure the loss in work productivity due to the
disease for employees that are engaged in “white
collar” positions to more completely capture lost
productivity.
As noted above, another limitation that leads to
potential underestimation of both work absence and
lost productivity is the fact that the cohort with gout
was restricted to cases that were diagnosed with ICD-9
codes during the study time frame. As self-reported
cases of gout are substantially higher than physician-
derived cases, there is a possibility that cases of gout
were not recorded because of misdiagnosis, the lack of
recording the diagnosis on the claims record, or the
possibility that a patient with gout simply did not seek
medical attention [36]. All of these possibilities lead to
underestimation of the impact of gout on both work
absence and lost productivity. Similarly, because
patients with gout who have been treated may have
fewer ﬂares and pain than untreated patients, another
form of underestimation may result from not taking
gout treatment into account in the analysis.
Some limitations arise from the data used. First, the
absenteeism data (sick leave, short- and long-term dis-
ability, and workers’ compensation) were not available
for some employees. This is due to the fact that some
employees are not eligible for all beneﬁts, and a small
number of employers have not tracked or supplied
these data. Second, the HCMS RRDb primarily
includes working-age persons, whereas the prevalence
of gout may be higher in older, nonworking popula-
tions. Nevertheless, the focus of the current analysis is
impact of gout on employee absence and productivity,
and the HCMS RRDb is consistent with the 2004 US
Employed Civilian Labor Force (N = 139.2 million) in
terms of age and sex proportions [37]. Nevertheless,
the HCMS database has a lower proportion of white
employees (65.4% vs. 82.8%), and higher proportions
of black (19.6% vs. 10.7%) and full-time employees
(86.6% vs. 72.0%). Furthermore, the median salary in
the current study was $42,044 compared with the US
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median salary of $33,176 [38]. The differences may be
due to the employers in the database being large and
nationally based. Lastly, claims data are collected for
reimbursement, not for research purposes. As a result,
these ﬁndings need to be replicated in a clinical study.
Further research is needed to determine the differ-
ences in lost days and productivity in early stages of
gout versus more chronic, severe stages. Research is
also needed to determine how much of work absence
and lost productivity is due to the pain accompanying
the condition versus the disability that accompanies
more chronic disease. This would include the contri-
bution of associated comorbidities of progressive gout,
such as urolithiasis, urate nephropathy, and/or tophi.
Finally, the contribution to work absence and lost pro-
ductivity of comorbidities commonly associated with
gout such as those found with metabolic syndrome
(obesity, hyperlipidemia, insulin resistance, and hyper-
tension), and/or the actual development of type 2 dia-
betes or cardiovascular disease should be evaluated.
The results of this type of detailed research allow
for employers to begin targeting speciﬁc treatment and
educational programs to not only improve the employ-
ee’s condition, but also improve work-place outcome
metrics. The current indications for treatment of gout
include that the patient has had: 1) at least two attacks
of gout (regardless of serum uric acid level); 2) tophi;
3) uric acid lithiasis; or 4) a serum uric acid greater
than 10 mg/dL. The goal is to reduce the serum uric
acid to less than 6 mg/dL [10,14]. Current treatment
for controlling hyperuricemia includes allopurinol, a
xanthine-oxidase inhibitor. Compliance with allopu-
rinol has been shown to be low [39], and the use is
associated with side effects in up to 5% of patients,
including gastrointestinal symptoms, bone marrow
suppression, and hypersensitivity syndrome [14].
Development of more effective treatment for hyperu-
ricemia may improve clinical and economic outcomes
and potentially reduce the number of gout ﬂares.
In conclusion, gout is a chronic, progressive disease
that, when untreated, may lead to permanent joint and
bone destruction, with resulting disability. This study
adds to the limited literature of the effect of gout on the
employed population and suggests that there is a sub-
stantial impact of this illness on health-related work
absence and objectively measured productive output.
Furthermore, it suggests that further research is
required to develop new and innovative solutions to
improve the status of the employee with gout.
The authors would like to thank Suzanne Novak, MD, PhD,
for her invaluable contributions to early drafts of this article.
Funding for this project was provided by TAP Pharmaceuti-
cal Products, Inc., Lake Forest, IL, USA.
Source of ﬁnancial support: TAP Pharmaceutical Products,
Inc., Lake Forrest, IL, USA.
References
1 Harris MD, Siegel LB, Alloway JA. Gout and hype-
ruricemia. Am Fam Physician 1999;59:925–34.
2 Kramer HM, Curhan G. The association between
gout and nephrolithiasis: the National Health and
Nutrition Examination Survey III, 1988–1994. Am J
Kidney Dis 2002;40:37–42.
3 Lawrence RC, Helmick CG, Arnett FC, et al. Esti-
mates of the prevalence of arthritis and selected mus-
culoskeletal disorders in the United States. Arthritis
Rheum 1998;41:778–99.
4 Adams PF, Hendershot GE, Marano MA. Current
estimates from the National Health Interview Survey,
1996. Vital Health Stat 10 1999;200.
5 Centers for Disease Control and Prevention, National
Center for Health Statistics. Vital and Health Statis-
tics: Current Estimates from the National Health
Interview Survey, 1988. Series 10, No. 173. Atlanta,
GA: Department of Health and Human Services.
Available from: http://www.cdc.gov/nchs/data/series/
sr_10/sr10_173.pdf [Accessed March 5, 2007].
6 Centers for Disease Control and Prevention, National
Center for Health Statistics. Vital and Health Statis-
tics: Current Estimates from the National Health
Interview Survey, 1996. Series 10, No. 200. Atlanta,
GA: Department of Health and Human Services.
Available from: http://www.cdc.gov/nchs/data/series/
sr_10/sr10_200.pdf [Accessed March 5, 2007].
7 Wallace KL, Riedel AA, Joseph-Ridge N, et al.
Increasing prevalence of gout and hyperuricemia over
10 years among older adults in a managed care popu-
lation. J Rheumatol 2004;31:1582–7.
8 Arromdee E, Michet CJ, Crowson CS, et al. Epidemi-
ology of gout: is the incidence rising? J Rheumatol
2002;29:2403–6.
9 Bieber JD, Terkeltaub RA. Gout: on the brink of novel
therapeutic options for an ancient disease. Art Rheum
2004;50:2400–14.
10 Kim KY, Schumacher HR, Hunsche E, et al. A litera-
ture review of the epidemiology and treatment of
acute gout. Clin Ther 2003;25:1593–617.
11 Reginato AJ. Gout and other crystal arthropathies. In:
Braunwald E, Fauci AS, Kasper DL, et al., eds. Har-
rison’s Principles of Internal Medicine (15th ed.). New
York: McGraw-Hill, 2001.
12 Cheng TT, Lai HM, Chiu CK, et al. A single-blind,
randomized, controlled trial to assess the efﬁcacy and
tolerability of rofecoxib, diclofenac sodium, and
meloxicam in patients with acute gouty arthritis. Clin
Ther 2004;26:399–406.
13 Cohen MD. The clinical manifestations of chronic
hyperuricemia: focus on gout. Medscape, 2004. Avail-
able from: http://www.medscape.com/viewarticle/
496670_11 [Accessed July, 2005].
14 Schlesinger N. Management of acute and chronic
gouty arthritis. Drugs 2004;64:2399–416.
15 Chorus AMJ, Boonen A, Miedema HS, et al. Em-
ployment perspectives of patients with ankylosing
spondylitis. Ann Rheum Dis 2002;61:693–9.
16 Chorus AMJ, Miedema HS, Wevers CWJ, et al. Work
factors and behavioural coping in relation to with-
236 Kleinman et al.
drawal from the labour force in patients with
rheumatoid arthritis. Ann Rheum Dis 2001;60:1025–
32.
17 Mancusco CA, Paget SA, Charlson ME. Adaptations
made by rheumatoid arthritis patients to continue
working: a pilot study of work place challenges and
successful adaptations. Arthritis Care Res 2000;13:
89–99.
18 Stewart WF, Ricci JA, Chee E, et al. Lost productivity
time and cost due to common pain conditions in the
US workforce. JAMA 2003;290:2443–54.
19 Cush JJ, Lipsky PE. Disorders of the joints. In: Braun-
wald E, Fauci AS, Kasper DL, et al., eds. Harrison’s
Principles of Internal Medicine (15th ed.). New York:
McGraw-Hill, 2001.
20 Muchmore L, Lynch WD, Gardner HH, et al. Preva-
lence of arthritis and associated joint disorders in an
employed population and the associated healthcare,
sick leave, disability, and workers’ compensation ben-
eﬁts cost and productivity loss for employers. J Occup
Environ Med 2003;45:369–78.
21 Elixhauser A, Steiner C, Palmer L. Clinical Classiﬁca-
tions Software, 2004. U.S. Agency for Healthcare and
Research. Available from: http://www.ahrq.gov/data/
hcup/css.htm#download [Accessed November, 2004].
Also available through HCUP Methods Series: Report
#2004–02 Comorbidity Software Documentation.
Available from: http://www.hcup-us.ahrq.gov/reports/
methods.jsp [Accessed November, 2004].
22 Kleinman NL, Brook RA, Rajagopalan K, et al. Lost
time, absence costs, and reduced productivity output
for employees with bipolar disorder. J Occup Environ
Med 2005;47:1117–24.
23 Charlson ME, Pompei P, Alex KL, et al. A new
method of classifying prognostic comorbidity in lon-
gitudinal studies: development and validation. J
Chronic Dis 1987;40:373–83.
24 Blough D, Madden C, Hornbrook M. Modeling risk
using generalized linear models. J Health Econ
1999;18:153–71.
25 Manning W, Mullahy J. Estimating log models: to
transform or not to transform? J Health Econ
2001;20:461–94.
26 Sarawate CA, Brewer KK, Yang W, et al. Gout medi-
cation treatment patterns and adherence to standards
of care from a manage care perspective. Mayo Clin
Proc 2006;81:925–34.
27 Lawrence RC, Hochberg MC, Kelsey JL, et al. Esti-
mates of the prevalence of selected arthritic and
musculoskeletal diseases in the United States. J Rheu-
matol 1989;16:427–41.
28 Roubenoff R, Klag MJ, Mead LA, et al. Incidence
and risk factors for gout in white men. JAMA
1991;266:3004–7.
29 Gignac MA. Arthritis and employment: an examina-
tion of behavioral coping efforts to manage workplace
activity limitations. Arthritis Rheum 2005;53:328–36.
30 Choi HK, Atkinson K, Karlson EW, et al. Obesity,
weight change, hypertension, diuretic use, and risk of
gout in men: the health professionals follow-up study.
Arch Intern Med 2005;165:742–8.
31 Choi HK, Atkinson K, Karlson EW, et al. Alcohol
intake and risk of incident gout in men: a prospective
study. Lancet 2004;363:1277–81.
32 Choi HK, Atkinson K, Karlson EW, et al. Purine-rich
foods, dairy and protein intake, and the risk of gout in
men. N Engl J Med 2004;350:1093–103.
33 US Census Bureau. United States Civilian Labor
Force. Available from: http://webs.wichita.edu/cedbr/
usclf.PDF#search=‘United%20states%20civilian%
20labor%20force’ [Accessed July, 2005].
34 Kaiser State Health Facts. Org: 50 State
Comparisons––Population Distribution by Insurance
Status 2003. Available from: http://www.
statehealthfacts.org [Accessed August, 2005].
35 US Census Bureau. Annual Estimates of the Popula-
tion by Selected Age Groups and Sex for the United
States: April 1, 2000 to July 1, 2004. Available from:
http://www.census.gov/popest/national/asrh/NC-
EST2004-sa.html [Accessed August, 2005].
36 Rao JK, Callahan LF, Helmick CG 3rd. Characteris-
tics of persons with self-reported arthritis and other
rheumatic conditions who do not see a doctor. J
Rheumatol 1997;24:169–73.
37 U.S. Bureau of Labor Statistics. Employment Status of
the Civilian Noninstitutional Population by Age, Sex,
and Race. Available from: ftp://ftp.bls.gov/pub/
special.requests/lf/aa2004/aat3.txt [Accessed June 4,
2006].
38 U.S. Bureau of Labor Statistics. Median Weekly Earn-
ings of Full-TimeWage and SalaryWorkers by Selected
Characteristics. Available from: ftp://ftp.bls.gov/pub/
special.requests/lf/aa2004/aat37.txt [Accessed June 4,
2006].
39 Riedel AA, Nelson M, Joseph-Ridge N, et al. Compli-
ance with allopurinol therapy among managed care
enrollees with gout: a retrospective analysis of admin-
istrative claims. J Rheumatol 2004;31:1575–81.
Gout’s Work Absence and Productivity Impact 237
